Berg has devoted considerable time, energy as well as capital in his latest venture, Berg Pharma in the search for new treatments for life-threatening diseases.
Carl Berg, who built up a billion dollar real estate empire in California’s Silicon Valley is nurturing his latest project, Berg Pharma which he established in 2007 to find modern treatments for some of the world’s most widespread diseases.
In order to find these treatments Berg Pharma uses a number of the most modern facets of communications technology, such as data analytics and processing as well as artificial intelligence in order to research cures for life threatening diseases such as cancer and stage two diabetes that have become increasingly prevalent in recent years.
Berg, who sold his real estate business in 2012 for $1.2 billion has not been taking life any easier, despite the fact that he is now well into his seventies. Instead, Berg Pharma is focusing on developing technology that will not only arrest the spread of “modern day maladies” in half the time that conventional medicine has been taking, with improved results and at considerably reduced costs.
The thinking behind Berg Pharma’s new approach is to look upon pharmaceutical research as a “Big Data” problem, which can be overcome through the utilization of artificial intelligence that will allow the company’s team of medical researchers to better understand the underlying biology behind diseases such as cancer and diabetes, Berg Pharma have a mission to rapidly develop treatments that will arrest the spread of these chronic diseases as well as put an end to the devastating effects that they bring on the people who suffer from these diseases.
Berg Pharma’s Interrogative Biology discovery platform has been developed to develop computer simulation of the proteins, lipids and metabolites found in both healthy and diseased cells. When these cells have been isolated, then the discovery platform will be capable of referring to algorithms, that are capable of identifying specific patterns in thye cells and how they healthy and diseased cells differ. Once the identification process has been completed, then the research team at Berg Pharma can begin to identify the specific proteins which can be utilized to return the diseased cell to a more normal mode.
Berg’s approach appears to be bringing results, with four treatments developed by the company advancing well through their clinical trials, with cautious optimism that the first treatment should be ready for release within the next two to three years.
Berg Pharma’s research is certainly beginning to capture the imagination of the pharmaceutical industry, with them being the recipients of the prestigious Frost & Sullivan award for innovation in drug discovery, while the company has now formed partnerships with a number of the most important medical schools and hospitals in the United States, including the Icahn School of Medicine at Mount Sinai, the University of Texas MD Anderson Cancer Center, and the US Department of Defense.
What makes Berg Pharmastand out from the traditional pharmaceutical companies, according to Carl Berg, is that it is based around a business model driven by computer analytics meaning that its research costs are lower. That means that the research department can be considerably less labor intensive, translated to the fact that the company currently has a payroll of 300, a mere fraction of what a traditional pharmaceutical company would normally employ to carry out a similar scale of research.
According to Carl Berg, his company’s success will be based not only on the strengths of their first class research team, and the most advanced technology that they have at their fingertips, but also to the long term business structure that Berg has put in place since he formed the company seven years ago.
And with a personal fortune estimated to be well over one billion dollars, Berg can afford to wait in the sincere belief that his philosophy will help to improve the life of millions.
Carl Berg graduated from the University of New Mexico in the late nineteen fifties and went on to build a real estate empire, the bulk of which he sold to property development giant Divco West in late 2012 for the sum of $1.3 billion. Currently, Berg, apart from his interest in Berg Pharma, holds considerable investments in Berg & Berg Enterprises, LLC , International Network Services and Valence Technologies.